Cells hoard polyamines to keep iron quiet, Whitehead team reports in Cell

A team led from the Whitehead Institute reports in Cell that polyamines, among the most abundant small molecules in cells, act as buffers for labile iron, holding the metal in a non-reactive state until the cell needs it ^[1][2][3]. That converts a decades-old curiosity, namely why cells maintain polyamine levels comparable to ATP when their best-known function needs only a fraction of that amount ^[4][5], into a possible lever on ferroptosis, since the authors say allowing iron overload to run could be used to kill cancer cells ^[6].

The route there started in an RNA lab. Ankur Jain, a Whitehead member and MIT associate professor of biology, and graduate student Pushkal Sharma first took up polyamines because the molecules bind RNA and shape how it folds ^[7][8]. To find what the surplus was doing, the group ran a genome-wide CRISPR-Cas9 screen in human cells under polyamine-depleted conditions ^[9]. The standout dependency was GPX4, the antioxidant enzyme that keeps membrane lipids from peroxidising and cells from dying by ferroptosis; the team calls this a synthetic lethal link between polyamines and iron homeostasis ^[10][11]. Polyamine-depleted cells also accumulated more of a second protein that sequesters iron in mineralised form ^[12], which is what a cell that has lost a buffer and is improvising another would look like.

The measurement is the part other labs can use. To test the buffering idea the team built a genetically encoded fluorescent reporter that makes living cells glow in proportion to their chemically reactive iron, giving a quantitative, real-time read under a microscope ^[13][14]. Run alongside a polyamine sensor the lab had built earlier, the pair produced what the researchers describe as a striking pattern as polyamine levels dropped ^[15]. The paper is titled "Polyamines buffer labile iron to suppress ferroptosis," and the authors write that the results "reposition polyamines as key regulators of iron homeostasis, with implications for ferroptosis-linked disease states and cellular redox balance" ^[3][16]. Jain and former postdoc Whitney Henry are co-senior and co-corresponding authors ^[17].

Two consequences follow, both hedged in the group's own telling, as reported by Genetic Engineering & Biotechnology News ^[22]. In oncology the implied play is a two-hit one: drain the polyamine buffer, and survival depends on GPX4, so blocking GPX4 in that state should let free iron do the damage that free iron does to DNA, proteins and membranes ^[18][20]. The group also suggests the work bears on early-onset Parkinson's disease, where mutations affect polyamine levels in neurons ^[19]. Neither line comes with a compound or an animal experiment in the account as published, which describes human cell screening and live-cell imaging ^[21].

Watch three things. Whether the iron reporter survives cross-validation against existing methods once other labs express it, because a quantitative sensor is worth only as much as its calibration. Whether polyamine depletion plus GPX4 inhibition has any therapeutic window: Jain notes that without polyamines cells stop growing and dividing at all ^[5], so the buffer is not a tumour-specific asset. And whether the iron-mineralising protein that rose under depletion is compensation or mechanism, which decides whether the node to drug is polyamine synthesis, GPX4, or the iron handling in between.